Regeneron Pharmaceuticals | REGN - Gross Profit On Sales

Stock Price
766.48
Daily Change
-8.58 -1.11%
Monthly
-1.30%
Yearly
6.15%
Q1 Forecast
718.61

Regeneron Pharmaceuticals reported $3.3B in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Astellas Pharma JPY 456.81B 38.02B Dec/2025
AstraZeneca USD 12.39B 406M Sep/2025
Biogen USD 1.68B 358.6M Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Incyte USD 1.27B 130.22M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
J&J USD 16.6B 118M Dec/2025
Kyowa Hakko Kirin JPY 90.6B 1.95B Sep/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 809M 791M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 3.02B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
United Therapeutics USD 602.1M 108.9M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025